H3 Biomedicine

H3 Biomedicine is a precision oncology research and development subsidiary of Eisai Co., Ltd. in the United States, focusing on advancing drugs from clinical trials to clinical practice. With a unique advantage in combining real-world clinical evidence with the latest advances in cancer genomics, H3 Biomedicine is developing a series of highly targeted therapies that have the potential to impact the future of cancer care and treatment.